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Abstract
Background: Opiate substitution therapy (OST) in the Ukraine was not provided until 2004. As part of
the introduction of OST, the first feasibility study was conducted in 2007. Six clinics in 6 cities were
involved in providing OST and collecting data. Methods: A total of 151 opiate-dependent patients were
given buprenorphine as a substitute, and a survey of substance use, HIV transmission risks, and legal
and social status was conducted at baseline and at 6 and 12-month follow-up. Results: Illegal substance
use and illegal activities and incomes were highly reduced, whereas employment rates and psychiatric
problems improved. Retention was comparatively high (79.5%) after 12 months. No significant adverse
events were reported. Conclusion: A successful implementation of OST in the Ukraine is feasible.
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 Introduction 
 Opiate substitution treatment (OST) has recently been 
shown to achieve similar positive outcomes in numerous 
countries with incomes ranging from low to high. Out-
comes include the reduction of heroin and other illicit 
opiate use, the reduction of HIV exposure-risk behaviors 
associated with injection drug use, the decrease of crim-
inal activities and the improvement of physical and men-
tal health  [1] . As part of this international study a first 
feasibility study was performed in Ukraine, whose 12-
month treatment data will be described in detail in the 
current report.
 According to a recent WHO estimation  [2, 3] there are 
between 325,000 and 425,000 injection drug users (IDUs) 
in Ukraine, of whom 144,000 are estimated to be HIV 
positive. To our knowledge, there are currently no esti-
mations or exact numbers for the mortality rate among 
IDUs.
 Despite this high prevalence of IDUs, until 2004 drug 
treatment programs relied on detoxification and absti-
nence-based rehabilitation in so called ‘narcological cen-
ters’  [4] . Because of political and clinical mistrust of OST, 
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 Background: Opiate substitution therapy (OST) in the 
Ukraine was not provided until 2004. As part of the introduc-
tion of OST, the first feasibility study was conducted in 2007. 
Six clinics in 6 cities were involved in providing OST and col-
lecting data.  Methods: A total of 151 opiate-dependent pa-
tients were given buprenorphine as a substitute, and a sur-
vey of substance use, HIV transmission risks, and legal and 
social status was conducted at baseline and at 6 and 12-
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tion was comparatively high (79.5%) after 12 months. No sig-
nificant adverse events were reported.  Conclusion: A 
successful implementation of OST in the Ukraine is feasible. 
 Copyright © 2009 S. Karger AG, Basel 
Published online: May 7, 2009
European
Addiction
cRe es ar h
 Michael Schaub, PhD 
 Research Institute for Public Health and Addiction 
 Konradstrasse 32 
 CH–8031 Zurich (Switzerland) 
 Tel. +41 44 448 1165, Fax +41 44 448 1171, E-Mail michael.schaub@isgf.uzh.ch 
 © 2009 S. Karger AG, Basel
1022–6877/09/0153–0157$26.00/0 
 Accessible online at:
www.karger.com/ear 
 Schaub /Subata /Chtenguelov /Weiler /
Uchtenhagen 
Eur Addict Res 2009;15:157–162158
buprenorphine was the only medication available for 
OST between 2004 and 2007. With the collaboration of 
the World Health Organization (regional office for Eu-
rope), the International HIV/AIDS Alliance, the Ukrai-
nian Institute for Public Health Policy and the manage-
ment and staff of existing treatment sites, the implemen-
tation of 6 buprenorphine maintenance treatment (BMT) 
sites started at the beginning of 2006. In June 2007, meth-
adone was approved by the Ukrainian Ministry of Health 
and will now also be made available for maintenance 
treatment. Nevertheless, the number of IDUs receiving 
agonist maintenance is still very low and the vast major-
ity of IDUs have not yet been reached by OST  [4] .
 There are several specific aspects of opioid use pat-
terns in the Ukraine that have to be kept in mind. Most 
Ukrainian IDUs do not use heroin but a self-made opioid 
called ‘shirka’, which is prepared from poppy straw in a 
common container shared among several users. A con-
taminated needle can result in contaminating the whole 
shirka and infecting other users. Also, ready-made shirka 
is available in preloaded unsterile syringes. These tend to 
be re-used and carry a high risk for contamination as they 
have usually been already used by the drug dealers them-
selves  [5, 6] .
 In addition to the low availability of agonist mainte-
nance in the Ukraine, access to antiretroviral therapy 
(ART) for IDUs was and still is low, and clinicians have 
tended to refuse ARTs to active IDUs, believing that they 
would be poorly adherent  [4] . However, recent evidence 
has emerged that integrating ART and OST in HIV-pos-
itive IDUs can optimize outcomes for both opiate addic-
tion and HIV infection status  [7] .
 This publication reports the first year treatment data 
of the first 6 buprenorphine treatment sites in the Ukraine 
(Kiev City AIDS center and Sociotherapy clinic, Donetsk 
Narcological Dispensary, Odessa Oblast Narcological 
Dispensary, AR Crimea Republican Narcological Dis-
pensary, Dnijpropetrovsk Narcological Dispensary and 
Mykolaiv Narcological Dispensary). More precisely, it fo-
cuses on the description of the outcomes of opiate-depen-
dent patients in this BMT program at baseline and at 6- 
and 12-month follow-up.
 Methods 
 Study Population 
 Since BMT started in 6 already existing treatment places, pa-
tients were asked if they were willing to start a BMT during a re-
cruitment period of 2–3 months. At the beginning of the recruit-
ment, this new treatment possibility was demanded by almost ev-
ery patient (n = 176). A patient recruitment list was prepared for 
documenting the basic characteristics of persons applying for 
OST at the sites, for documenting their eligibility and their even-
tual admittance to the program by treatment staff at their sites. 
Patients with signs of severe cognitive impairment, mental retar-
dation, severe behavior disturbances or psychotic symptoms were 
excluded from the study. Furthermore, patients who were expect-
ing hospitalization or imprisonment were also excluded. In order 
to be eligible for participation in the study, patients had to fulfil 
dependence diagnosis for opiates according to ICD-10, be at least 
18 years old, be living in permanent residence within commuting 
distance of the respective OST clinic and provide informed con-
sent to treatment and the treatment regime, including blood test-
ing, and to their participation in the study follow-up interviews. 
153 eligible patients were recruited for the OST program and the 
study. Only 2 patients refused to give informed consent. Finally, 
a total of 151 patients were included in the study.
 Patients had to ingest their individual dose of buprenorphine 
at the OST site on a daily basis. According to the Ukrainian guide-
lines for good practice in BMT, higher buprenorphine doses were 
prescribed at the beginning of treatment to suppress withdrawal 
syndromes (typically 12–14 mg). The doses were then gradually 
reduced to the maintenance dose, which usually was from 2 to 
8 mg. For the most part, this was on the initiative of the patients, 
who usually had plans to leave the program in the long run due to 
the inconvenience of coming each day to be supervised while they 
took the BMT. Patients were also tested for HIV in the first 2 
weeks of the BMT study. Hepatitis B and C status were taken from 
the medical records at the beginning of the study. Care was pro-
vided to seropositive patients outside the OST sites by AIDS cen-
tres (further HIV testing, laboratory monitoring and ART provi-
sion). All OST and HIV/AIDS services were free of charge.
 Treatment Staff and Monitoring 
 At all sites, relevant professionals (doctors, psychiatrists, nurs-
es, psychologists, and social workers) were in the team taking care 
of the somatic, psychiatric, psychological and social needs of pa-
tients. In all teams at all project sites, competence to work with 
drug-dependent persons was assured by recurring training ac-
cording to the Ukrainian guidelines for good practice in BMT, as 
well as by supervision on request. The monitoring and evaluation 
protocol and plan was developed at the Research Institute for 
Public Health and Addiction at Zurich University, in consultation 
with the WHO Euro-office, the International HIV/AIDS Alli-
ance, the OST program managers and the Ukrainian Institute of 
Public Health Policy. An international consultant from Vilnius 
University visited all OST sites.
 Data Collection 
 Patient descriptions, baseline and follow-up data (6 and 12 
months after intake) were collected by use of a clinical record 
form. An external interviewer assessed history and patterns of 
substance use with the Addiction Severity Index (ASI)  [8] at base-
line and follow-up. Furthermore, the external interviewer admin-
istered the Blood-Borne Virus Transmission Risk Assessment 
Questionnaire BBV-TRAQ  [9] at baseline and follow-up to deter-
mine risk behaviors. The Ukrainian Institute of Public Health 
Policy translated both questionnaires into Ukrainian. Data on 
status, regime, treatment received, adverse events, compliance 
and termination were entered daily by OST treatment staff into 
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standardized patient records prepared by the same institute. Pa-
tients who dropped out of the study were contacted if possible in 
order to find out more about their reasons for dropping out and 
to motivate them to participate in the nearest follow-up interview. 
Reasons for dropout were noted on the patients’ clinical report 
forms.
 Data Management and Analyses 
 Data were transmitted electronically to the Ukrainian Insti-
tute of Public Health Policy and entered into a relational database. 
All patient data were coded and recorded anonymously. Differ-
ences between baseline and follow-up data were tested by repeat-
ed-measures analysis of variance test statistic for those patients 
who stayed in treatment. In case of categorical variables, appli-
cable data percentages were specified and   2 tests for dependent 
and independent samples were applied, respectively. The reasons 
why patients dropped out of the study were reported on the clini-
cal report form. Finally, a Cox regression analysis for months in 
treatment was performed to investigate effects of baseline charac-
teristics, mean buprenorphine dose, baseline HIV status, and 
baseline ASI and BBV-TRAQ scores as predictors. Dropouts’ 
baseline data were further compared with baseline data of those 
patients who reached the 12 month follow-up. P  ! 0.05 was con-
sidered statistically significant. All data were analyzed with the 
statistical software package SPSS, version 15.
 Results 
 Sample Characteristics 
 A total of 151 BMT patients entered the study at base-
line. Seventy-five percent of all patients were male, had 
an average age of 35.2 ( 8 7.7), declared on average 10.8 
( 8 2.0) years of education and 1.8 ( 8 1.9) years of profes-
sional education. More than half of all patients were mar-
ried (54.3%), only 4.6% stated they lived in irregular 
housing conditions (homeless) and 38.1% stated they held 
a legally paid job. By far the longest history of substance 
use related to ‘other opiates’ (13.5  8 7.6 years), followed 
by cannabis use (6.6  8 8.8 years) and polydrug use (6.0 
 8 6.3 years). In contrast, the use of other substances, and 
especially of heroin, was more recent. Barbiturate use 
went back 1.4  8 3.0 years and the use of sedatives and 
tranquillizers 2.7  8 4.5 years. Accordingly, the range of 
drug use history was greatest between use of other opiates 
(almost exclusively shirka) and use of heroin.
 The large majority of former treatments received were 
for drug problems, with an average of 5.6 ( 8 7.8) treat-
ments per patient. Previous treatments for alcohol prob-
lems (0.1  8 0.6 episodes) and psychiatric problems (0.3 
 8 0.9 episodes) were much less frequent. 75.3% of all pa-
tients had been arrested at least once. 15.2% of all patients 
had been participating in groups of Alcoholics Anony-
mous or Narcotics Anonymous.
 More than half of all patients (51.7%) were found to be 
HIV positive at entry into the program. In regard to the 
infection stage, clinical AIDS syndrome was diagnosed 
in 12.3% of the HIV infected patients at baseline. Hepa-
titis C virus seropositivity was reported in 15.8% (17.2% 
missing) of patients and the rate for hepatitis B seroposi-
tivity was 3.3% (17.2% missing). There was a deficit in 
tuberculosis diagnosis (9.5% were tuberculosis positive 
but data were missing in 62.9% of patients).
 Treatment Outcomes 
 Substance use (last 30 days) decreased significantly for 
other opiate use (F 120; 119  = 187.864, p  ! 0.001), on the ASI 
alcohol (F 120; 119  = 5.451, p  ! 0.05) and drug score (F 120; 119 
 = 197.265, p  ! 0.001) between baseline, 6 and 12 month 
follow-up ( table 1 ). Meanwhile, the mean buprenorphine 
dosage remained approximately the same (F 120; 119  = 
0.423, n.s.), but the prescription of ART medication in-
creased (  2 120; 2 = 44.912, p  ! 0.001).
 The occurrence of somatic disorders decreased for di-
gestion (  2 120; 2  = 9.234, p  ! 0.01) and urination (  2 120; 2  = 
11.375, p  ! 0.01) problems. Moreover, fewer patients were 
HIV positive (  2 120; 2 = 102.282, p  ! 0.001) and patients’ 
ASI medical score improved (F 120; 119 = 6.831, p  ! 0.05) 
after 12 months. Psychiatric problems were also less ob-
served as measured by the ASI psychiatric problems score 
(F 120; 119 = 46.015, p  ! 0.001).
 Concerning the BBV-TRAQ (transmission risk behav-
iors), there were considerable decreases for injection vi-
rus transmission risk behaviors (F 120; 119 = 51.209, p  ! 
0.001) and somewhat less pronounced for sexual virus 
transmission risks (F 120; 119 = 8.165, p  ! 0.01). The BBV-
TRAQ skin penetration scores did not change over the 
12-month period (F 120; 119  = 0.010, n.s.).
 Employment (paid working days) F 120; 119  = 14.767, p  ! 
0.001; ASI score employment (F 120; 119  = 5.295, p  ! 0.05) 
and legal status (criminal activity last 30 days) F 120; 119 = 
22.127, p  ! 0.001; ASI score for legal problems F 120; 119 = 
51.154, p  ! 0.001; persons with illegal problems   2 120; 2 = 
35.121, p  ! 0.001 improved consistently in all applied 
measures over time ( table 1 ).  The same was the case for 
the ASI family problems score (F 120; 119 = 16.223, p  ! 
0.001), emotional abuse (F 120; 119 = 16.266, p  ! 0.001) and 
sexual abuse (F 120; 119 = 9.735, p  ! 0.01).
 Last but not least, the number of HIV-positive patients 
in treatment who received ART medication increased 
during the study period (  2 42; 2 = 44.912, p  ! 0.001).
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 Dropouts 
 A total of 22 (14.6%) patients dropped out of the study 
after the 6-month follow-up and an additional 9 (5.9%) 
patients dropped out after the 12-month follow-up. Rea-
sons for these 33 (20.5%) dropouts were: systematic non-
attendance and intake of illegal drugs (11 patients); im-
prisonment (6 patients); treatment regime violation (2 pa-
tients); absence of euphoric sensations so the patient 
wished to stop treatment (8 patients); move to a ‘12-step’ 
rehabilitation program (1 patient), move to religious re-
habilitation center (1 patient); admission to hospital
(1 patient); move to another city (1 patient); unknown
(1 patient), and hospitalization followed by death in hos-
pital (1 patient). None of the dropout patients could be 
motivated for the next follow-up interview.
 The Cox regression for month in treatment (  2 148; 23 = 
33.641, n.s.) revealed no significant effects on patients 
who dropped out for the covariates age, sex, age of first 
Table 1. Baseline, 6- and 12-month follow-up of BMT
Baseline 6 months 12 months F/2 p
Patients, n (% of baseline) 151 (100.0) 129 (85.4) 120 (79.5) – –
Medication
Buprenorphine dosage, mg/day 10.483.7 9.984.3 10.284.3 0.423 n.s.
BMT treatment regime change, % – 23.3 11.2 0.210 n.s.
Antiretroviral medication, % 10.6 18.9 28.3 19.143 <0.001
Substance use in last 30 daysa
Heroin 0.180.6 0.080.0 0.080.0 2.818 n.s.
Other opiate 18.4812.7 0.180.9 0.381.7 187.864 <0.001
Sedative 5.589.7 2.285.9 2.586.8 2.487 n.s.
Alcohol intoxication 0.683.5 0.381.7 0.481.5 0.049 n.s.
Cocaine  0.080.0 0.080.0 0.080.0 –
Amphetamines 0.382.5 0.080.0 0.682.7 0.388 n.s.
Inhalants 0.080.0 0.080.0 0.080.0 –
ASI score alcohol 0.180.1 0.080.1 0.080.1 5.451 <0.05
ASI score drugs 0.380.1 0.180.1 0.180.1 197.265 <0.001
Somatic disorders
Normal weight, % 55.8 59.8 58.1 3.407 n.s.
Trophic ulcer, % 7.5 3.3 2.7 4.571 n.s.
Digestion problems, % 28.6 13.9 19.8 9.234 <0.01
Urination problems, % 10.3 0.8 4.5 11.375 <0.01
Sexual problems, % 13.6 11.5 11.7 1.188 n.s.
HIV positive, % 51.7 51.7 27.2 102.282 <0.001
ASI score medical 0.380.3 0.280.3 0.280.2 6.831 <0.05
Risk taking behaviour (BBV-TRAQ)
Injecting score 12.4811.8 1.182.5 2.485.1 51.209 <0.001
Sexual score 7.887.9 4.786.6 5.086.7 8.165 <0.01
Skin penetration score 2.683.2 1.382.2 2.6810.2 0.010 n.s.
Psychiatric problems (ASI score) 0.380.2 0.180.2 0.180.2 46.015 <0.001
Employment and legal status
Paid working days in last 30 days 8.4811.3 14.2811.8 14.4811.3 14.767 <0.001
ASI score employment 0.780.2 0.780.3 0.780.3 5.295 <0.05
Criminal activity in last 30 daysa 3.988.6 0.381.6 0.080.0 22.127 <0.001
ASI score for legal problems 0.280.2 0.180.1 0.180.1 51.154 <0.001
Persons with illegal income last 30 days, % 26.5 4.7 2.8 35.121 <0.001
Family problems
ASI score family 0.280.2 0.180.1 0.180.1 16.223 <0.001
Emotional abuse (last 30 days)a 1.380.5 1.280.4 1.180.3 16.266 <0.001
Physical abuse (last 30 days)a 1.180.3 1.080.2 1.080.1 9.735 <0.001
F = Repeated-measures analysis of variance test statistic; 2 = Friedman test statistic.
a Data are mean 8 SD number of instances in last 30 days. 
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drug use, years of use of the assessed substances and poly-
drug use, years of previous drug treatments, average bu-
prenorphine dose, baseline HIV status, baseline ASI and 
BBV-TRAQ scores. Patients who dropped out differed at 
baseline from the patients staying in treatment on the ASI 
drugs domain score (dropouts 0.34  8 0.13, others 0.25  8 
0.13, t 151; 149  = 3.491, p  ! 0.001), family domain score 
(dropouts 0.29  8 0.21, others 0.19  8 0.19, t 151; 149 = 2.447, 
p  ! 0.05) and the psychiatric domain score (dropouts 0.35 
 8 0.18, others 0.25  8 0.20, t 151; 149 = 2.676, p  ! 0.01). 
Dropouts further differed on the baseline BBV track-
score injecting practices (dropouts 16.55  8 10.40, others 
11.30  8 11.88, t 151; 149  = 2.246, p  ! 0.05) and sexual prac-
tices (dropouts 5.03  8 6.80, others 8.55  8 8.07, t 151; 149 = 
–2.230, p  ! 0.05). There were no significant differences 
between the dropouts and the patients staying in treat-
ment for buprenorphine dose at baseline (dropouts 10.98 
 8 3.22 mg/day, others 10.31  8 3.76 mg/day, t 151; 149 = 
0.896), mean buprenorphine dose (dropouts 10.97  8 3.24 
mg/day, others 10.10  8 3.55 mg/day, t 151; 149 = 1.306), HIV 
status at baseline (dropouts 1.55  8 0.55, others 1.45  8 
0.51, t 148; 146 = 0.944), in the duration of all assessed life-
time substance use (e.g. years of other opiates: dropouts 
11.68  8 7.77, others 14.03  8 7.47, t 151; 149 = 1.548) and in 
the numbers of previous addiction treatment stays (drop-
outs 5.46  8 7.07, others 6.13  8 10.20, t 151; 149 = 0.427).
 Discussion 
 The study outcomes during the 12 months of treat-
ment were impressive. There were large reductions in use 
of illegal and non-prescribed substances, illegal activi-
ties, illegal incomes and risk-taking behaviors. Patients’ 
employment rates increased and their psychiatric prob-
lems improved.
 It also revealed that the target group of chronic Ukrai-
nian opiate (shirka) users, who were relapsing after many 
previous drug-free treatments, were willing to enter OST 
and that the great majority remained in treatment during 
a 1-year observation period. This study also documented 
that almost all patients gave their consent to participate 
in an extensive data collection used for evaluation pur-
poses. Getting their medication at the OST sites by daily 
supervised intake restricted their freedom to work and 
relaxation during weekends and vacations.
 The reason why one fifth of patients dropped out of 
the study could be ascribed to the usual dropout reasons 
for these types of studies (systematic non-attendance and 
intake of illegal drugs, absence of euphoric sensations 
and therefore the patient wishing to stop treatment) for 
patients who tended to carry a higher burden of drug, 
family and psychiatric problems at baseline. However, 
these dropout rates could also have emerged from spe-
cific Ukrainian OST prescription regulation problems 
(some patients had to be admitted to hospital, or were 
imprisoned within the 12 months, although patients who 
were expecting hospitalization or imprisonment were ex-
cluded from the study at baseline).
 Thus, one of the biggest obstacles that emerged during 
the study period was that OST could not be continued for 
patients who had to be hospitalized. Hospitals had no li-
cense to store controlled medications. Likewise, impris-
onments lead to interruption of substitution treatment. 
Another problem that emerged during the study was that 
although the provision of ART medication for HIV-posi-
tive patients at the AIDS centers increased during the 12 
months, we must assume that not all patients who would 
profit from ART medication actually received it.
 The main strength of the current study is that it pro-
vides the first systematically collected data on the feasi-
bility of OST in Ukraine and in a comparatively large 
sample of specific homemade opiate (shirka) injectors. 
However, there are also some limitations to the current 
study: (1) it had to rely on self-declaration when assessing 
frequency of substance use, since systematic urine testing 
would have been too expensive; (2) patients were recruit-
ed within already existing (previously abstinence-orient-
ed) treatment places what could have led to a selection 
bias; (3) there were some language restrictions (e.g. the 
ASI and the BBV-TRAQ had to be translated into Ukrai-
nian but could not be validated as part of the current 
study).
 In consideration of the current study results, we con-
clude that a successful and adequate implementation of 
OST in the Ukraine is feasible. Scale-up of OST in the 
Ukraine is highly recommended.
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